US7097839B1
(en)
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
US6321164B1
(en)
|
1995-06-07 |
2001-11-20 |
Akzo Nobel N.V. |
Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
|
US6429017B1
(en)
*
|
1999-02-04 |
2002-08-06 |
Biomerieux |
Method for predicting the presence of haemostatic dysfunction in a patient sample
|
US6898532B1
(en)
|
1995-06-07 |
2005-05-24 |
Biomerieux, Inc. |
Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
|
US7030152B1
(en)
|
1997-04-02 |
2006-04-18 |
The Brigham And Women's Hospital, Inc. |
Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
|
US6727102B1
(en)
|
1997-06-20 |
2004-04-27 |
Leuven Research & Development Vzw |
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
|
US6502040B2
(en)
|
1997-12-31 |
2002-12-31 |
Biomerieux, Inc. |
Method for presenting thrombosis and hemostasis assay data
|
ATE253223T1
(de)
*
|
1998-08-27 |
2003-11-15 |
Mayo Foundation |
Verfahren und materialien zur diagnose instabiler angina
|
US6309888B1
(en)
*
|
1998-09-04 |
2001-10-30 |
Leuven Research & Development Vzw |
Detection and determination of the stages of coronary artery disease
|
ATE282208T1
(de)
*
|
1999-02-04 |
2004-11-15 |
Bio Merieux Inc |
Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben
|
EP1767222A1
(en)
*
|
1999-08-31 |
2007-03-28 |
The Brigham And Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
EP1520590A1
(en)
*
|
1999-08-31 |
2005-04-06 |
The Brigham and Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
WO2001015744A1
(en)
*
|
1999-08-31 |
2001-03-08 |
The Brigham And Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
GB9929140D0
(en)
*
|
1999-12-10 |
2000-02-02 |
Univ Geneve |
Diagnostic assay for stroke
|
US7179612B2
(en)
*
|
2000-06-09 |
2007-02-20 |
Biomerieux, Inc. |
Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
GB0019172D0
(en)
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
WO2002038794A2
(en)
*
|
2000-11-09 |
2002-05-16 |
The Brigham And Women's Hospital, Inc. |
Cardiovascular disease diagnostic and therapeutic targets
|
AU3084802A
(en)
*
|
2000-12-14 |
2002-06-24 |
Brigham & Womens Hospital |
Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
|
US6855509B2
(en)
*
|
2000-12-19 |
2005-02-15 |
Instrumentation Laboratory Company |
Protein S functional assay and kit therefor
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
WO2002062207A2
(en)
|
2001-01-02 |
2002-08-15 |
The Cleveland Clinic Foundation |
Myeloperoxidase, a risk indicator for cardiovascular disease
|
US6500630B2
(en)
|
2001-01-12 |
2002-12-31 |
Mayo Foundation For Medical Education And Research |
Marker for inflammatory conditions
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
DK1413331T3
(da)
*
|
2001-01-26 |
2007-12-10 |
Schering Corp |
Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer
|
WO2002067958A1
(en)
*
|
2001-02-21 |
2002-09-06 |
Merck & Co., Inc. |
Method for determining efficacy of reverse cholesterol transport enhancing agents
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
US7713705B2
(en)
|
2002-12-24 |
2010-05-11 |
Biosite, Inc. |
Markers for differential diagnosis and methods of use thereof
|
US20040253637A1
(en)
*
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
US7608406B2
(en)
|
2001-08-20 |
2009-10-27 |
Biosite, Inc. |
Diagnostic markers of stroke and cerebral injury and methods of use thereof
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
MXPA04002573A
(es)
*
|
2001-09-21 |
2004-06-18 |
Schering Corp |
Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
|
EP1451577A4
(en)
|
2001-11-05 |
2006-03-15 |
Brigham & Womens Hospital |
SOLUBLE CD40L (CD154) AS A PROGNOSEMARKER FOR ATHEROSCLEROSIS DISEASES
|
ATE436017T1
(de)
*
|
2001-11-09 |
2009-07-15 |
Medstar Res Inst |
Verfahren zur verwendung physiologischer marker für die abschätzung eines herz-kreislauf-risikos
|
AU2002352726A1
(en)
|
2001-11-15 |
2003-06-10 |
Galileo Laboratories, Inc. |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
US20040071633A1
(en)
*
|
2002-02-19 |
2004-04-15 |
Wright Samuel D. |
Method for determining efficacy of reverse cholesterol transport enhancing agents
|
ES2375181T3
(es)
|
2002-05-09 |
2012-02-27 |
The Brigham And Women's Hospital, Inc. |
1l 1rl-1 como un marcador de enfermedades cardiovasculares.
|
US7763649B2
(en)
*
|
2002-07-29 |
2010-07-27 |
Cardax Pharmaceuticals, Inc. |
Carotenoid analogs or derivatives for controlling connexin 43 expression
|
US7521584B2
(en)
*
|
2002-07-29 |
2009-04-21 |
Cardax Pharmaceuticals, Inc. |
Carotenoid analogs or derivatives for the inhibition and amelioration of disease
|
US7345091B2
(en)
*
|
2002-07-29 |
2008-03-18 |
Cardax Pharmaceuticals, Inc. |
Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
|
US20050059635A1
(en)
*
|
2002-07-29 |
2005-03-17 |
Lockwood Samuel Fournier |
Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
|
US20050004235A1
(en)
*
|
2002-07-29 |
2005-01-06 |
Lockwood Samuel Fournier |
Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
|
US20050049248A1
(en)
*
|
2002-07-29 |
2005-03-03 |
Lockwood Samuel Fournier |
Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
|
US20050059659A1
(en)
*
|
2002-07-29 |
2005-03-17 |
Lockwood Samuel Fournier |
Carotenoid analogs or derivatives for controlling C-reactive protein levels
|
US7375133B2
(en)
*
|
2002-07-29 |
2008-05-20 |
Cardax Pharmaceuticals, Inc. |
Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
|
WO2004011423A2
(en)
*
|
2002-07-29 |
2004-02-05 |
Hawaii Biotech, Inc. |
Structural carotenoid analogs for the inhibition and amelioration of disease
|
US20050143475A1
(en)
*
|
2002-07-29 |
2005-06-30 |
Lockwood Samuel F. |
Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
|
US20050009788A1
(en)
*
|
2002-07-29 |
2005-01-13 |
Lockwood Samuel Fournier |
Carotenoid ester analogs or derivatives for controlling connexin 43 expression
|
US20050148517A1
(en)
*
|
2002-07-29 |
2005-07-07 |
Lockwood Samuel F. |
Carotenoid ether analogs or derivatives for controlling connexin 43 expression
|
US20050026874A1
(en)
*
|
2002-07-29 |
2005-02-03 |
Lockwood Samuel Fournier |
Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
|
US7320997B2
(en)
*
|
2002-07-29 |
2008-01-22 |
Cardax Pharmaceuticals, Inc. |
Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
|
US7723327B2
(en)
*
|
2002-07-29 |
2010-05-25 |
Cardax Pharmaceuticals, Inc. |
Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
|
NZ539624A
(en)
|
2002-09-27 |
2008-08-29 |
Martek Biosciences Corp |
Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
|
US7851486B2
(en)
*
|
2002-10-17 |
2010-12-14 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US7507531B2
(en)
*
|
2002-10-17 |
2009-03-24 |
Decode Genetics Chf. |
Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
|
US20040097433A1
(en)
*
|
2002-11-15 |
2004-05-20 |
Sekhar Boddupalli |
Chroman derivatives for the reduction of inflammation symptoms
|
CA2508823A1
(en)
*
|
2002-12-12 |
2004-07-01 |
Activbiotics, Inc. |
Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
|
US20050026168A1
(en)
*
|
2002-12-13 |
2005-02-03 |
Genesis Group Inc. |
Method for the detection of risk factors associated with myocardial infarction
|
GB0229747D0
(en)
*
|
2002-12-20 |
2003-01-29 |
Axis Shield Asa |
Assay
|
ATE406364T1
(de)
|
2003-03-07 |
2008-09-15 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
JP4589919B2
(ja)
*
|
2003-03-07 |
2010-12-01 |
シェーリング コーポレイション |
高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US20040192660A1
(en)
*
|
2003-03-12 |
2004-09-30 |
Mullally John P. |
Protocol for improving vision
|
WO2004080414A2
(en)
*
|
2003-03-12 |
2004-09-23 |
Mullally John P |
Composition and method for treating inflammations by reducing c-reactive protein
|
US20050026979A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Maha Ghazzi |
Methods for treating inflammation and inflammation-associated diseases with a statin and ether
|
EP1670445A2
(en)
*
|
2003-09-17 |
2006-06-21 |
Decode Genetics EHF. |
Methods of preventing or treating recurrence of myocardial infarction
|
EP1673465A4
(en)
*
|
2003-09-29 |
2008-04-30 |
Biosite Inc |
PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS
|
US20080085329A1
(en)
*
|
2003-10-22 |
2008-04-10 |
Fred Hutchinson Cancer Research Center, Inc. |
Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
|
WO2005046675A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Jordan Holtzman |
Methods for enhancing glutathione peroxidase activity
|
US9408891B2
(en)
*
|
2003-11-12 |
2016-08-09 |
The Trustees Of The University Of Pennsylvania |
Methods of using gelsolin to treat or prevent bacterial sepsis
|
WO2005046454A2
(en)
*
|
2003-11-12 |
2005-05-26 |
Trustrees Of The University Of Pennsylvania |
Methods of using gelsolin to treat or prevent bacterial sepsis
|
ATE546734T1
(de)
|
2003-12-05 |
2012-03-15 |
Cleveland Clinic Foundation |
Risikomarker für eine herzkreislaufkrankheit
|
US20080279843A1
(en)
*
|
2003-12-09 |
2008-11-13 |
Essential Skincare, Llc |
Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20050181451A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Bates Harold M. |
Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
|
WO2005083430A1
(en)
*
|
2004-02-25 |
2005-09-09 |
Massachusetts Eye & Ear Infirmary |
Biomarkers for age-related macular degeneration (amd)
|
US20060058269A1
(en)
*
|
2004-04-14 |
2006-03-16 |
Lockwood Samuel F |
Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
|
WO2005102356A1
(en)
*
|
2004-04-14 |
2005-11-03 |
Hawaii Biotech, Inc. |
Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
|
KR101314461B1
(ko)
*
|
2004-05-12 |
2013-10-07 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
감염 치료를 위한 겔솔린의 용도
|
EP1750719A2
(en)
|
2004-05-19 |
2007-02-14 |
Boehringer Ingelheim International GmbH |
Treatment of diseases associated with altered level of amyloid beta peptides
|
US9372190B2
(en)
*
|
2004-05-26 |
2016-06-21 |
Region Nordjylland |
Method of evaluation of the relative risk of developing atherosclerosis in patients
|
US8027791B2
(en)
|
2004-06-23 |
2011-09-27 |
Medtronic, Inc. |
Self-improving classification system
|
US8335652B2
(en)
|
2004-06-23 |
2012-12-18 |
Yougene Corp. |
Self-improving identification method
|
US20060020043A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Roger Berlin |
Methods and compositions for reducing C-reactive protein
|
US7378396B2
(en)
*
|
2004-08-11 |
2008-05-27 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
WO2006031592A1
(en)
*
|
2004-09-09 |
2006-03-23 |
University Of Massachusetts |
Disease markers for early stage atherosclerosis
|
US20060088860A1
(en)
*
|
2004-09-13 |
2006-04-27 |
Lipomics Technologies, Inc. |
Metabolite markers for weight management
|
WO2006042192A2
(en)
|
2004-10-06 |
2006-04-20 |
The Brigham And Womens's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
CN101115496B
(zh)
*
|
2004-12-06 |
2012-03-07 |
加州大学评议会 |
改善微动脉的结构和功能的方法
|
US8822535B2
(en)
*
|
2005-04-20 |
2014-09-02 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
MX2007013430A
(es)
*
|
2005-04-29 |
2008-03-19 |
Univ California |
Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
|
US20070099239A1
(en)
*
|
2005-06-24 |
2007-05-03 |
Raymond Tabibiazar |
Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
|
JP5140575B2
(ja)
*
|
2006-02-14 |
2013-02-06 |
ポーラ化成工業株式会社 |
美白用の化粧料
|
US8440622B2
(en)
*
|
2006-03-15 |
2013-05-14 |
The Brigham And Women's Hospital, Inc. |
Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
|
HUE056086T2
(hu)
*
|
2006-03-15 |
2022-01-28 |
Brigham & Womens Hospital Inc |
Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére
|
DK2848938T3
(da)
|
2006-04-24 |
2017-11-13 |
Critical Care Diagnostics Inc |
Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
|
ATE517341T1
(de)
*
|
2006-04-27 |
2011-08-15 |
Critical Care Diagnostics Inc |
Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
|
JP5377289B2
(ja)
*
|
2006-05-01 |
2013-12-25 |
クリティカル ケア ダイアグノスティクス インコーポレイテッド |
心血管疾患の診断方法
|
EP2995951B1
(en)
*
|
2006-05-02 |
2019-02-13 |
Critical Care Diagnostics, Inc. |
Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
|
EP2030025A2
(en)
|
2006-06-07 |
2009-03-04 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
CA2712834A1
(en)
*
|
2007-02-05 |
2008-08-14 |
Aarhus Universitet |
A method for diagnosing atherosclerotic plaques by measurement of cd36
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
WO2009032722A1
(en)
*
|
2007-08-29 |
2009-03-12 |
The Cleveland Clinic Foundation |
Carbamylated proteins and risk of cardiovascular disease
|
WO2009073839A1
(en)
*
|
2007-12-05 |
2009-06-11 |
The Cleveland Clinic Foundation |
Trimethylamine compounds as risk predictors of cardiovascular disease
|
HUE032875T2
(en)
|
2008-01-25 |
2017-11-28 |
Massachusetts Gen Hospital |
Diagnostic and therapeutic applications of gelsolin in renal failure
|
PT2269063E
(pt)
|
2008-04-18 |
2013-11-27 |
Critical Care Diagnostics Inc |
Predição do risco de eventos cardíacos adversos maiores
|
US20090298923A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Genmedica Therapeutics Sl |
Salicylate Conjugates Useful for Treating Metabolic Disorders
|
WO2010014771A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Ore Pharmaceuticals Inc. |
Romazarit for treating metabolic diseases
|
US11835503B2
(en)
|
2009-05-28 |
2023-12-05 |
The Cleveland Clinic Foundation |
TMA-formation inhibitor treatment for elevated TMA-containing compound diseases
|
US10241093B2
(en)
|
2009-05-28 |
2019-03-26 |
The Cleveland Clinic Foundation |
Trimethylamine-containing compounds for diagnosis and prediction of disease
|
JP5379616B2
(ja)
|
2009-09-09 |
2013-12-25 |
株式会社日立製作所 |
粥状硬化性動脈硬化のマーカー因子と用途
|
AU2010319290A1
(en)
*
|
2009-11-13 |
2012-05-24 |
Bg Medicine, Inc. |
Risk factors and prediction of myocardial infarction
|
ES2750126T3
(es)
|
2011-03-17 |
2020-03-25 |
Critical Care Diagnostics Inc |
Procedimientos de predicción del riesgo de un resultado clínico adverso
|
US8708906B1
(en)
*
|
2011-09-07 |
2014-04-29 |
Allen J. Orehek |
Method for the prevention of dementia and Alzheimer's disease
|
WO2014031764A1
(en)
|
2012-08-21 |
2014-02-27 |
Critical Care Diagnostics, Inc. |
Multimarker risk stratification
|
EP2931876B1
(en)
*
|
2012-12-12 |
2019-05-29 |
Mesoblast, Inc. |
Treatment of diseases of endothelial dysfunction and inflammation
|
EP3140429B1
(en)
|
2014-05-05 |
2020-02-19 |
Medtronic Inc. |
Methods for scd, crt, crt-d, or sca therapy identification and/or selection
|
CN107074923B
(zh)
|
2014-07-31 |
2021-08-03 |
Uab研究基金会 |
Apoe模拟肽及对清除血浆胆固醇的较高效力
|
WO2016040570A2
(en)
|
2014-09-12 |
2016-03-17 |
Children's Medical Center Corporation |
Dietary emulsion formulations and methods for using the same
|
FI127416B
(en)
*
|
2016-09-29 |
2018-05-31 |
Oy Medix Biochemica Ab |
Cardiovascular risk assessment method
|